{"id":"W2807978154","doi":"10.1136/annrheumdis-2018-eular.3646","title":"SAT0271 Secukinumab, a fully human anti-interleukin-17a monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52-week treatment period","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital","funders":"Myriad Genetics; UCB Pharma; Pfizer; Eli Lilly and Company; Amgen","keywords":"Medicine; Psoriatic arthritis; Ankylosing spondylitis; Secukinumab; Immunogenicity; Concomitant; BASDAI; Internal medicine; Rheumatoid arthritis; Gastroenterology; Pharmacokinetics; Psoriasis Area and Severity Index; Methotrexate; Adalimumab; Adverse effect; Pharmacology; Immunology; Antibody; Psoriasis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005681154,0.0002430479,0.0004591221,0.0002196834,0.0002602147,0.0003270541,0.0001131007,0.0003069554,0.0008074359],"category_scores_gemma":[0.001123074,0.0001501669,0.000354439,0.0002174868,0.0001511777,0.0002618034,0.0001264811,0.0004422296,0.0001785496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002234193,"about_ca_system_score_gemma":0.0001565621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005602556,"about_ca_topic_score_gemma":0.0006834229,"domain_scores_codex":[0.9996703,0.0001295157,0.00003186879,0.00004860364,0.00005660241,0.00006315112],"domain_scores_gemma":[0.9995809,0.0001257727,0.0001257772,0.00003440485,0.00005423256,0.00007887526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04635525,0.002341752,0.7383813,0.0002083157,0.0004937795,0.002246646,0.0005423102,0.0008062925,0.1157602,0.00006950977,0.0009231424,0.09187143],"study_design_scores_gemma":[0.0004058625,0.01849409,0.9674839,0.00001327358,0.0002935669,0.002993337,0.0002366905,0.001243161,0.00773132,0.00003381596,0.001051216,0.00001975421],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999305,0.0003309377,0.00004896451,0.00001935595,0.000005476227,0.000004854093,0.0000226105,0.000004500696,0.0002582505],"genre_scores_gemma":[0.9997278,0.00004081659,0.0000256104,0.00001988047,0.000005576612,0.000002926098,0.00005744145,0.000001067898,0.0001187816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008074359,"threshold_uncertainty_score":0.003004551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009129718896250853,"score_gpt":0.2401444432605067,"score_spread":0.2310147243642558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}